At the end of the day the company needed to raise significant...

At the end of the day the company needed to raise significant amounts of cash for the coming year as AVR embarks on its FDA trials in the US. Given we are in a depressed market Funds aren't openly throwing around cash for any deal, especially companies that are pre profit. The options were obviously used as a sweetener to get the big players to stump up. Otherwise IMO funds would have expected a pretty substantial discount of ~$19-$20 a share without the options to get the deal across. I'm sure they discussed both cases and both have their flaws. Agree the options are a hard pill to swallow at present.

Markets IMO will wash through the post capital raising traders soon enough and the stock will reset for its next phase. One which hopefully brings good news as First patients in the US are implanted in early Q2 (April/May). Continued Strong Data and results IMO should create tailwinds and share appreciation. The FDA trials will obviously carry a lot more weight strategically then our current cohort of patients given how big a role the FDA plays in the medical field. It's all about the physicians and medical company's who will be focused on the data, which to date AVRs results has shown to exceed those of current market leaders.